HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) A correction has been published Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Related articles in BJP Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Harrison, P. J. Search for Related Content PubMed PubMed Citation Articles by Harrison, P. J.

Metabotropic glutamate receptor agonists for schizophrenia

Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK. Email: paul.harrison{at}psych.ox.ac.uk

Declaration of interest

I have received honoraria from various pharmaceutical companies, including Lilly (who funded the trial discussed here), for giving non-promotional lectures, chairing scientific meetings or for consultancy work. I hold an unrestricted research grant from GlaxoSmithKline.

Paul J Harrison is a Professor of Psychiatry in Oxford. He trained in Oxford and London and his research focuses on the molecular neurobiology of psychosis.

A drug acting at metabotropic glutamate receptors has recently been reported to be an effective antipsychotic, breaking the rule that only dopamine receptor-blocking drugs have this property. The finding complements accumulating evidence that glutamatergic abnormalities are important in the pathophysiology of schizophrenia.

Related articles in BJP:

From the Editor's desk

Peter Tyrer
BJP 2008 192: 160. [Full Text]  

This article has been cited by other articles:

				P. Harrison, L. Lyon, L. Sartorius, P. Burnet, and T. Lane Review: The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia J Psychopharmacol, May 1, 2008; 22(3): 308 - 322. [Abstract] [PDF]